Discover how Chroma is expanding our impact.
HBV 2023 International Meeting: Development of HBV-targeting epigenetic repressors with deep, durable in vivo silencing of viral markers
ASGCT IO 2023: Durable epigenetic editing for generation of multiplex-edited T cells without chromosomal rearrangements
ASGCT 2023: Development of a human PCSK9-targeting epigenetic editor with durable, near-complete in vivo silencing
ASGCT 2023: Multiplexed editing without chromosomal rearrangements using epigenetic editors